Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.
--------
Question: The decision by Cleveland County District Judge Thad Balkman in Norman, Oklahoma, came in the first case to go to trial out of 2,700 nationally by states, counties and cities seeking to hold drug companies responsible for the deadly epidemic. Balkman reduced the amount he had awarded in August by $107 million after agreeing with New Brunswick, New Jersey-based J&J that he had made a math error. J&J said it will appeal, and that the award and finding of liability were “neither supported by the facts nor the law.”  A spokesman for Oklahoma Attorney General Mike Hunter said that office is reviewing the decision and will formally respond within the next few days. Opioids were involved in almost 400,000 overdose deaths from 1999 to 2017, according to the U.S. Centers for Disease Control and Prevention. Following a non-jury trial, Balkman ruled in August that Oklahoma had proven that J&J engaged in misleading marketing about the benefits of painkillers, and that their addictive risks caused a public nuisance in the form of the opioid crisis. Hunter had sought to have J&J pay $17 billion to help fund addiction treatment and other services to repair damage from the opioid epidemic over the next 30 years. Balkman, however, awarded only enough money for one year of programs, saying Oklahoma failed to support its claims regarding the need to abate the epidemic in future years. Following the August ruling, Oklahoma asked Balkman for permission to return to his courtroom annually to prove those costs, but Balkman on Friday maintained his prior ruling. J&J, meanwhile, argued that it deserved a $355 million credit, reflecting pre-trial settlements by the drugmakers Purdue Pharma LP and Teva Pharmaceutical Industries Ltd.  Balkman concluded on Friday that state law did not allow such credits. Last month, J&J and four other companies proposed a $48 billion settlement framework to resolve all of the opioid cases they face, with J&J paying $4 billion. Lawyers for the local governments have opposed the proposal. If approved, the settlement would let J&J resolve some of the thousands of product liability lawsuits it faces. The company also faces litigation over whether its baby powder causes cancer, a claim it denies.

Answer: Oklahoma judge reduces Johnson & Johnson opioid payout to $465 million.


Question: Cannabis products are becoming available in Ohio dispensaries over the next few months following delays in rolling out the program last year. Patients need a physician’s recommendation to buy medical marijuana from such dispensaries to treat allowable conditions, which currently include AIDS, Alzheimer’s and Parkinson’s diseases, cancer, epilepsy and several other maladies. The medical board on Wednesday reviewed petitions for adding several new conditions and settled on six, which also include general anxiety disorder, depression, insomnia, and opioid addiction. Experts will review these conditions for possible inclusion on the list of allowable treatments. A final decision comes within six months.

Answer: State to consider 6 conditions to treat with medical pot.


Question: The story notes the an additional $20 per mammogram with CAD when billed to Medicare. With the newer technology, costs to public health would increase via additional screening and unnecessary biopsies, and treatment would increase for cancers that may never become problematic (i.e. some forms of DCIS or ductal carcinoma in situ). The story provides data that there was little positive difference between radiologists' and CAD detection of cancer via mammogram images. However, the story does not mention results of any other evaluations of the technology (e.g. how it has been used in UK and other countries where results did show benefit in terms of increased detection of cancer). The story mentions that the newer technology may result in over treatment as there are more false positives with the CAD technology vs. radiologists' analysis alone. In a recent study published in the New England Journal of Medicine, there was 20% increase in biopsy rates after mammographers used the CAD software. The article does not present the study well. It was an observational study of select practices in the US – not randomized, not controlled and there was no information about how representative these samples were, especially the centers that used CAD. The story presented some key results but virtually nothing about the study design. The story does not engage in disease mongering or suggest that women should opt for mammograms at centers that have the new CAD technology. The story provides many clinical perspectives on the CAD technology. The reporter interviews not only the study author and the author of an accompanying NEJM editorial, but also clinicians and radiologists who talk about use of CAD in practice. Interviews with clinicians who provide their rationale for not using the CAD technology provide excellent balance to the story. The story discusses the continued benefit of mammography for early detection of breast cancer. The story highlights that computer-assisted screening does not replace human judgment in interpretation of radiological films. The story mentions that about 30% of mammography centers use computer-aided detection (CAD) technology. The story mentions that CAD is a newer method of reading mammographies, but in a recent observational trial it was no better–and may have produced more false positives–than images read and interpreted by radiologists alone. The story does not rely solely on a press release for information, and there is independent reporting and sources cited not affiliated with the recently published data on CAD.

Answer:
Doubts on mammogram software